1,649 research outputs found
Prior information in fluorescence molecular tomography based on multispectral fluorescence emission
Spectral Separation of Quantum Dots within Tissue Equivalent Phantom Using Linear Unmixing Methods in Multispectral Fluorescence Reflectance Imaging
Introduction
Non-invasive Fluorescent Reflectance Imaging (FRI) is used for accessing physiological and molecular processes in biological media. The aim of this article is to separate the overlapping emission spectra of quantum dots within tissue-equivalent phantom using SVD, Jacobi SVD, and NMF methods in the FRI mode.
Materials and Methods
In this article, a tissue-like phantom and an optical setup in reflectance mode were developed. The algorithm of multispectral imaging method was then written in Matlab environment. The setup included the diode-pumped solid-state lasers at 479 nm, 533 nm, and 798 nm, achromatic telescopic, mirror, high pass and low pass filters, and EMCCD camera. The FRI images were acquired by a CCD camera using band pass filter centered at 600 nm and high pass max at 615 nm for the first region and high pass filter max at 810 nm for the second region. The SVD and Jacobi SVD algorithms were written in Matlab environment and compared with a Non-negative Matrix Factorization (NMF) and applied to the obtained images.
Results
PSNR, SNR, CNR of SVD, and NMF methods were obtained as 39 dB, 30.1 dB, and 0.7 dB, respectively. The results showed that the difference of Jacobi SVD PSNR with PSNR of NMF and modified NMF algorithm was significant (p<0.0001). The statistical results showed that the Jacobi SVD was more accurate than modified NMF.
Conclusion
In this study, the Jacobi SVD was introduced as a powerful method for obtaining the unmixed FRI images. An experimental evaluation of the algorithm will be done in the near future
Advances in optical imaging for pharmacological studies
Imaging approaches are an essential tool for following up over time representative parameters of in vivo models, providing useful information in pharmacological studies. Main advantages of optical imaging approaches compared to other imaging methods are their safety, straight-forward use and cost-effectiveness. A main drawback, however, is having to deal with the presence of high scattering and high absorption in living tissues. Depending on how these issues are addressed, three different modalities can be differentiated: planar imaging (including fluorescence and bioluminescence in vivo imaging), optical tomography, and optoacoustic approaches. In this review we describe the latest advances in optical in vivo imaging with pharmacological applications, with special focus on the development of new optical imaging probes in order to overcome the strong absorption introduced by different tissue components, especially hemoglobin, and the development of multimodal imaging systems in order to overcome the resolution limitations imposed by scattering.JR acknowledges support from the EC FP7 CIG grant HIGH-THROUGHPUT TOMO, and MINECO grant FIS 2013-41802-R MESO-IMAGIN
High resolution tumor targeting in living mice by means of multispectral optoacoustic tomography
BACKGROUND: Tumor targeting is of high clinical and biological relevance, and major efforts have been made to develop molecular imaging technologies for visualization of the disease markers in tissue. Of particular interest is apoptosis which has a profound role within tumor development and has significant effect on cancer malignancy. METHODS: Herein, we report on targeting of phosphatidylserine-exposing cells within live tumor allograft models using a synthetic near infrared zinc(II)-dipicolylamine probe. Visualization of the probe biodistribution is performed with whole body multispectral optoacoustic tomography (MSOT) system and subsequently compared to results attained by planar and tomographic fluorescence imaging systems. RESULTS: Compared to whole body optical visualization methods, MSOT attains remarkably better imaging capacity by delivering high-resolution scans of both disease morphology and molecular function in real time. Enhanced resolution of MSOT clearly showed that the probe mainly localizes in the vessels surrounding the tumor, suggesting that its tumor selectivity is gained by targeting the phosphatidylserine exposed on the surface of tumor vessels. CONCLUSIONS: The current study demonstrates the high potential of MSOT to broadly impact the fields of tumor diagnostics and preclinical drug development
Image reconstruction in fluorescence molecular tomography with sparsity-initialized maximum-likelihood expectation maximization
We present a reconstruction method involving maximum-likelihood expectation
maximization (MLEM) to model Poisson noise as applied to fluorescence molecular
tomography (FMT). MLEM is initialized with the output from a sparse
reconstruction-based approach, which performs truncated singular value
decomposition-based preconditioning followed by fast iterative
shrinkage-thresholding algorithm (FISTA) to enforce sparsity. The motivation
for this approach is that sparsity information could be accounted for within
the initialization, while MLEM would accurately model Poisson noise in the FMT
system. Simulation experiments show the proposed method significantly improves
images qualitatively and quantitatively. The method results in over 20 times
faster convergence compared to uniformly initialized MLEM and improves
robustness to noise compared to pure sparse reconstruction. We also
theoretically justify the ability of the proposed approach to reduce noise in
the background region compared to pure sparse reconstruction. Overall, these
results provide strong evidence to model Poisson noise in FMT reconstruction
and for application of the proposed reconstruction framework to FMT imaging
DNA-Based Nanocarriers to Enhance the Optoacoustic Contrast of Tumors In Vivo
Optoacoustic tomography (OT) enables non-invasive deep tissue imaging of optical contrast at high spatio-temporal resolution. The applications of OT in cancer imaging often rely on the use of molecular imaging contrast agents based on near-infrared (NIR) dyes to enhance contrast at the tumor site. While these agents afford excellent biocompatibility and minimal toxicity, they present limited optoacoustic signal generation capability and rapid renal clearance, which can impede their tumor imaging efficacy. In this work, a synthetic strategy to overcome these limitations utilizing biodegradable DNA-based nanocarrier (DNA-NC) platforms is introduced. DNA-NCs enable the incorporation of NIR dyes (in this case, IRDye 800CW) at precise positions to enable fluorescence quenching and maximize optoacoustic signal generation. Furthermore, these DNA-NCs show a prolonged blood circulation compared to the native fluorophores, facilitating tumor accumulation by the enhanced permeability and retention (EPR) effect. In vivo imaging of tumor xenografts in mice following intravenous administration of DNA-NCs reveals enhanced OT signals at 24 h when compared to free fluorophores, indicating promise for this method to enhance the optoacoustic signal generation capability and tumor uptake of clinically relevant NIR dyes.This work was funded by a Cancer Research UK Cambridge Centre Pump Prime Research Grant (KAZA/071 and KNZA-151). K.N.B. acknowledges funding by ERASMUS + and a PROMOS scholarship awarded by the DAAD. J.J. and S.E.B. are funded by the EPSRC-CRUK Cancer Imaging Centre in Cambridge and Manchester (C197/A16465); CRUK (C14303/A17197, C47594/A16267, C9545/A29580) and the EU-FP7-agreement FP7- PEOPLE-2013-CIG-630729. S.H.A. acknowledges funding by the University of Zaragoza (UZ2018-CIE-04) and by Fundación Ibercaja y Universidad de Zaragoza (JIUZ-2018-CIE-04). S.H.A. and A.P. acknowledge funding by the Gobierno de Aragón-FSE (E47_20R).Peer reviewe
Prediction of Proapoptotic Anticancer Therapeutic Response Based on Visualization of Death Ligand-Receptor Interaction and Specific Marker of Cellular Proliferation
Emerging targeted therapeutics hold great promise for the treatment of human cancer. However there are still challenges for selecting patients that most likely will benefit from targeted drugs. One of the major limitations of classical imaging methods is the significant delay to provide quantifiable and objective evidence of response to cancer therapy. Molecular imaging may be useful in targeted drug development by assessing the target expression and drug-target interaction, and predicting therapeutic response in both preclinical and clinical settings. The apoptosis pathway triggered by the Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) receptors is a potential target for therapeutic intervention. TRAIL and its proapoptotic receptor agonistic monoclonal antibodies are being developed as targeted therapeutics in the treatment of human cancer. It is our hypothesis that visualization of proapoptotic receptors and binding of their agonists to proapoptotic receptors can noninvasively predict proapoptotic response if the pathway is intact. Hence the objective of this work is to develop efficient multimodality molecular imaging methods to predict proapoptotic anticancer therapy response before or at the very early stage of treatment. Towards this goal, we have labeled proapoptotic receptor agonists (PARAs) with near-infrared (NIR) fluorescent dyes to image PARAs binding to their targets expressed on the cell surface in cultured cells and in human tumor xenografts grown subcutaneously in immunodeficient mice. Both in vitro and in vivo studies demonstrated that imaging PARAs binding to their targets was well correlated with proapoptotic anticancer therapeutic response when TRAIL signaling pathway was intact. To pursue a more general molecular imaging marker that can predict anticancer therapeutic response even when the signaling pathway is impaired, we explored a novel radiotracer for positron emission tomography (PET) imaging [(18)F]-3\u27-fluoro-3\u27-deoxy-L-thymidine ([(18)F]-FLT), an analogue of thymidine and a specific marker of DNA replication and cellular proliferation. Our results suggested that early changes in [(18)F]-PET may not only predict the tumor histological response to anticancer therapeutics but also determine superiority of one treatment regimen over another. In summary our proof-of-concept studies show that multimodality molecular imaging will greatly aid in accelerating anticancer drug approval process and improving survival and response rates in hard-to-treat cancer
Multimodal Multispectral Optical Endoscopic Imaging for Biomedical Applications
Optical imaging is an emerging field of clinical diagnostics that can address the growing
medical need for early cancer detection and diagnosis. Various human cancers are
amenable to better prognosis and patient survival if found and treated during early
disease onset. Besides providing wide-field, macroscopic diagnostic information similar
to existing clinical imaging techniques, optical imaging modalities have the added
advantage of microscopic, high resolution cellular-level imaging from in vivo tissues in real
time. This comprehensive imaging approach to cancer detection and the possibility of
performing an ‘optical biopsy’ without tissue removal has led to growing interest in the
field with numerous techniques under investigation. Three optical techniques are
discussed in this thesis, namely multispectral fluorescence imaging (MFI), hyperspectral
reflectance imaging (HRI) and fluorescence confocal endomicroscopy (FCE). MFI and
HRI are novel endoscopic imaging-based extensions of single point detection techniques,
such as laser induced fluorescence spectroscopy and diffuse reflectance spectroscopy.
This results in the acquisition of spectral data in an intuitive imaging format that allows
for quantitative evaluation of tissue disease states. We demonstrate MFI and HRI on
fluorophores, tissue phantoms and ex vivo tissues and present the results as an RGB
colour image for more intuitive assessment. This follows dimensionality reduction of the
acquired spectral data with a fixed-reference isomap diagnostic algorithm to extract only
the most meaningful data parameters. FCE is a probe-based point imaging technique
offering confocal detection in vivo with almost histology-grade images. We perform FCE
imaging on chemotherapy-treated in vitro human ovarian cancer cells, ex vivo human
cancer tissues and photosensitiser-treated in vivo murine tumours to show the enhanced
detection capabilities of the technique. Finally, the three modalities are applied in
combination to demonstrate an optical viewfinder approach as a possible minimally-invasive
imaging method for early cancer detection and diagnosis
Recommended from our members
Non-Invasive Photoacoustic Imaging of In Vivo Mice with Erythrocyte Derived Optical Nanoparticles to Detect CAD/MI.
Coronary artery disease (CAD) causes mortality and morbidity worldwide. We used near-infrared erythrocyte-derived transducers (NETs), a contrast agent, in combination with a photoacoustic imaging system to identify the locations of atherosclerotic lesions and occlusion due to myocardial-infarction (MI). NETs (≈90 nm diameter) were fabricated from hemoglobin-depleted mice erythrocyte-ghosts and doped with Indocyanine Green (ICG). Ten weeks old male C57BL/6 mice (n = 9) underwent left anterior descending (LAD) coronary artery ligation to mimic vulnerable atherosclerotic plaques and their rupture leading to MI. 150 µL of NETs (20 µM ICG,) was IV injected via tail vein 1-hour prior to photoacoustic (PA) and fluorescence in vivo imaging by exciting NETs at 800 nm and 650 nm, respectively. These results were verified with histochemical analysis. We observed ≈256-fold higher PA signal from the accumulated NETs in the coronary artery above the ligation. Fluorescence signals were detected in LAD coronary, thymus, and liver. Similar signals were observed when the chest was cut open. Atherosclerotic lesions exhibited inflammatory cells. Liver demonstrated normal portal tract, with no parenchymal necrosis, inflammation, fibrosis, or other pathologic changes, suggesting biocompatibility of NETs. Non-invasively detecting atherosclerotic plaques and stenosis using NETs may lay a groundwork for future clinical detection and improving CAD risk assessment
- …